Ceritinib is a novel triple negative breast cancer therapeutic agent

por Dong, Shengli, Yousefi, Hassan, Savage, Isabella Van, Okpechi, Samuel C., Wright, Maryl K., Matossian, Margarite D., Collins-Burow, Bridgette M., Burow, Matthew E., Alahari, Suresh K.
Publicado 2022